Risk-sharing in the Pharmaceutical Industry The Case of Out-licensing /
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Collectivité auteur: | |
| Format: | Électronique eBook |
| Langue: | English |
| Publié: |
Heidelberg :
Physica-Verlag HD : Imprint: Physica,
2006.
|
| Édition: | 1st ed. 2006. |
| Collection: | Contributions to Management Science,
|
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1007/3-7908-1668-X |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- Key Issues in Managing Pharmaceutical Innovation
- Risk-sharing as New Paradigm in Pharma R&D Collaborations
- Case Studies on Risk-sharing in Pharma R&D Collaborations
- Characteristics of Risk-sharing in Pharma R&D Collaborations
- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
- Conclusion.